Remove 2029 Remove Pharmaceuticals Remove Therapies Remove Trials
article thumbnail

Thirteen potential blockbuster drugs to watch in 2024

Drug Discovery World

Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. The therapy has shown positive results in Phase III trials in both breast and lung cancer.

Drugs 173
article thumbnail

Diabetic eye disease: The urgent need for early, non-invasive treatments

Drug Discovery World

Dr Catherine Beech , CEO at Exonate and Dr Pete Adamson , CSO at Breye Therapeutics discuss the need for better therapies to treat diabetic retinal disease and current progress in the field. Selective targeting would enable the therapy to treat the disease whilst not impacting the natural processes of VEGF. In 2019 there were >14.2

Disease 162
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The trends driving ELRIG Drug Discovery 2022

Drug Discovery World

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Cell and gene therapies. In 2021, levels of investment hit an all-time high at $22.7

Drugs 130
article thumbnail

What is the largest CRO in the US?

Vial

Introduction Contract research organizations (CROs) are essential in pharmaceutical research and development (R&D). billion by 2029. Throughout its journey, PPD has been committed to consistent quality and execution, customer-aligned service, and continuous innovation to accelerate clinical trial execution.